Literature DB >> 33274720

Emerging Players in Prostate Cancer-Bone Niche Communication.

Giulia Furesi1, Martina Rauner1, Lorenz C Hofbauer2.   

Abstract

Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts have been proposed as major contributors of osteotropism by PCa. Here, we highlight the emerging role of PCa-derived extracellular vesicles (EVs) in reprogramming osteoblasts and support of premetastatic niche formation. We also develop the concept of cancer-associated osteoblasts (CAOs) and outline the potential of PCa cells to acquire an osteoblastic phenotype, termed osteomimicry, as two strategies that PCa utilizes to create a favorable protected niche. Finally, we delineate future research that may help to deconstruct the complexity of PCa osteotropism.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bone metastasis; cancer-associated osteoblasts; osteomimicry; prostate cancer; tumor-derived extracellular vesicles; tumor-educated osteoblasts

Year:  2020        PMID: 33274720     DOI: 10.1016/j.trecan.2020.09.006

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  12 in total

Review 1.  Role of prostate and bone stromal cells on prostate cancer progression.

Authors:  Sofia Karkampouna; Marianna Kruithof-de Julio; George N Thalmann
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

Review 2.  Microfluidic Co-culture Platforms for Studying Osteocyte Regulation of Other Cell Types under Dynamic Mechanical Stimulation.

Authors:  Chun-Yu Lin; Xin Song; Kimberly Seaman; Lidan You
Journal:  Curr Osteoporos Rep       Date:  2022-09-23       Impact factor: 5.163

Review 3.  Evolving cancer-niche interactions and therapeutic targets during bone metastasis.

Authors:  Robert L Satcher; Xiang H-F Zhang
Journal:  Nat Rev Cancer       Date:  2021-10-05       Impact factor: 69.800

4.  Exosomal miRNAs from Prostate Cancer Impair Osteoblast Function in Mice.

Authors:  Giulia Furesi; Antonio Miguel de Jesus Domingues; Dimitra Alexopoulou; Andreas Dahl; Matthias Hackl; Johannes R Schmidt; Stefan Kalkhof; Thomas Kurth; Hanna Taipaleenmäki; Stefanie Conrad; Christine Hofbauer; Martina Rauner; Lorenz C Hofbauer
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

5.  Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment.

Authors:  Xiangyu Zhang; Qingbin Liu; Tingting Zhang; Pei Gao; Hui Wang; Lu Yao; Jingwen Huang; Shulong Jiang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

6.  Bone Marrow-Derived Stem Cell Factor Regulates Prostate Cancer-Induced Shifts in Pre-Metastatic Niche Composition.

Authors:  Brittni M Foster; Lihong Shi; Koran S Harris; Chirayu Patel; Victoria E Surratt; Kendall L Langsten; Bethany A Kerr
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

7.  Androgen receptor variant-7 regulation by tenascin-c induced src activation.

Authors:  Rintu Thomas; John Michael Jerome; Truong D Dang; Eric P Souto; Joshua N Mallam; David R Rowley
Journal:  Cell Commun Signal       Date:  2022-08-10       Impact factor: 7.525

8.  The impacts of exosomes on bone metastatic progression and their potential clinical utility.

Authors:  Jenna Ollodart; Kelly F Contino; Gagan Deep; Yusuke Shiozawa
Journal:  Bone Rep       Date:  2022-07-21

Review 9.  Bone Health Management in the Continuum of Prostate Cancer Disease.

Authors:  Ettickan Boopathi; Ruth Birbe; Sunday A Shoyele; Robert B Den; Chellappagounder Thangavel
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

Review 10.  The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone.

Authors:  Andy Göbel; Stefania Dell'Endice; Nikolai Jaschke; Sophie Pählig; Amna Shahid; Lorenz C Hofbauer; Tilman D Rachner
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.